ORCA
Online Research @ CardiffÂ
Browse by Current Cardiff authors
![[up]](/style/images/multi_up.png)
Up a levelNumber of items: 3.
Knapper, Steven  ORCID: https://orcid.org/0000-0002-6405-4441, Dillon, Laura W., Babu, Malavika, Thomas, Abin ORCID: https://orcid.org/0000-0002-8283-6762, Thomas, Ian, Hourigan, Christopher S, Andrew, Georgia, Dillon, Richard, Gilkes, Amanda, Marquez Almuina, Nuria, King, Sophie, McCarthy, Nicholas, Bahr, Reem, Al-Ali, Rasha W, Stone, Louisa, Coats, Tom, Byrne, Jennifer, Green, Simone, Overgaard, Ulrik Malthe, Sellar, Rob S., Dennis, Mike, Mehta, Priyanka, Hills, Robert, Freeman, Sylvie D. and Russell, Nigel H
2025.
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18 trial.
Blood
10.1182/blood.2025031006
|
|
Knapper, Steven, Thomas, Abin ORCID: https://orcid.org/0000-0002-8283-6762, King, Sophie, Thomas, Ian, Gilkes, Amanda, Irwin, Sarah, Sellar, Robert, Green, Simone, Overgaard, Ulrik Malthe, Mehta, Priyanka, Dennis, Mike, Freeman, Sylvie and Russell, Nigel
2023.
S131: a randomised assessment of the sequential addition of the kinase inhibitor Quizartinib to intensive chemotherapy in older acute myeloid leukaemia (AML) patients: results from the NCRI AML18 trial [Abstract].
HemaSphere
7
, pp. 69-70.
10.1097/01.hs9.0000967436.08196.70
|
|
|
|
Freeman, Sylvie D, Thomas, Abin, Thomas, Ian, Vyas, Paresh, Gilkes, Amanda, Metzner, Marlen, Jakobsen, Niels Asger, Kennedy, Alison, Moore, Amy, Marquez Almuina, Nuria, Burns, Sarah, King, Sophie, Andrew, Georgia M., Gallagher, Kathleen M.E., Sellar, Rob, Cahalin, Paul, Weber, Duruta, Dennis, Mike, Mehta, Priyanka, Knapper, Steve ORCID: https://orcid.org/0000-0002-6405-4441 and Russell, Nigel H.
2022.
A randomized comparison of the fractionated versus single dose schedule of Gemtuzumab Ozogamicin at induction with determinants of benefit for older AML patients: UK NCRI AML18 trial results.
Blood
140
(S1)
, pp. 532-533.
10.1182/blood-2022-162245
|
|